We first assessed the impact of CDK4/6 inhibition in vivo using our recently described MMTV-rtTA/tetO-HER2 transgenic mouse model of mammary carcinoma 6
. Here we use mouse models of breast carcinoma and other solid tumours to show that selective CDK4/6 inhibitors not only induce tumour cell cycle arrest, but also promote anti-tumour immunity. We confirm this phenomenon through transcriptomic analysis of serial biopsies from a clinical trial of CDK4/6 inhibitor treatment for breast cancer. The enhanced antitumour immune response has two underpinnings. First, CDK4/6 inhibitors activate tumour cell expression of endogenous retroviral elements, thus increasing intracellular levels of double-stranded RNA. This in turn stimulates production of type III interferons and hence enhances tumour antigen presentation. Second, CDK4/6 inhibitors markedly suppress the proliferation of regulatory T cells. Mechanistically, the effects of CDK4/6 inhibitors both on tumour cells and on regulatory T cells are associated with reduced activity of the E2F target, DNA methyltransferase 1. Ultimately, these events promote cytotoxic T-cell-mediated clearance of tumour cells, which is further enhanced by the addition of immune checkpoint blockade. Our findings indicate that CDK4/6 inhibitors increase tumour immunogenicity and provide a rationale for new combination regimens comprising CDK4/6 inhibitors and immunotherapies as anti-cancer treatment.
We first assessed the impact of CDK4/6 inhibition in vivo using our recently described MMTV-rtTA/tetO-HER2 transgenic mouse model of mammary carcinoma 6 . Cells derived from these tumours express the retinoblastoma (RB) tumour suppressor and arrest in response to CDK4/6 inhibition 6 . In three independent experiments, the CDK4/6 inhibitor abemaciclib caused regression of bulky tumours, evidenced by an ~ 40% reduction in tumour volume at the 12-day end point (Fig. 1a) . As expected, abemaciclib reduced tumour cell proliferation (Extended Data Fig. 1a) . Expression analysis across a panel of 3,826 cancer-related genes from MMTV-rtTA/tetO-HER2 tumours (Fig. 1b) showed that abemaciclib downregulated genes within gene ontology (GO) and gene set enrichment analysis (GSEA) terms relating to cell cycle, mitosis, and E2F targets (Extended Data Fig. 1b-d) . Strikingly, only two GO process terms were significantly enriched for genes upregulated by abemaciclib: 'antigen processing and presentation of peptide antigen' and 'antigen processing and presentation' (Fig. 1c) . Specifically, genes encoding mouse major histocompatibility complex (MHC) class I molecules were upregulated in abemaciclib-treated tumours (H2d1, H2k1, and Β2m), as were genes directing peptide cleavage (Erap1), peptide transporters (Tap1 and Tap2), and transporter-MHC interactions (Tapbp) (Fig. 1d) . Moreover, abemaciclib treatment in vitro increased expression of the orthologous genes in human breast cancer cell lines (MDA-MB-453, MCF7, and MDA-MB-361) ( Fig. 1e and Extended Data Fig. 2a ) and palbociclib, another CDK4/6 inhibitor, yielded similar results (Extended Data Fig. 2b ). Importantly, treatment with either agent increased cellsurface expression of β 2M and MHC class I proteins (Extended Data  Fig. 2c ). The CDK4/6 inhibitor-induced increase in expression of antigen processing and presentation genes was also observed in a patientderived breast cancer xenograft of a treatment-refractory breast cancer (PDX 14-07, previously described 6 ) ( Fig. 1f) . Furthermore, analysis of The Cancer Genome Atlas (TCGA) data 7 revealed that breast cancers harbouring CCND1 amplification (that is, enhanced CDK4/6 activity) display significantly lower expression of HLA-A, HLA-B, and HLA-C than non-amplified tumours (Extended Data Fig. 2d ).
To determine the functional consequences of increased antigen presentation gene expression, we treated ovalbumin (OVA)-expressing mouse cancer cell lines (MMTV-PyMT-S2WTP3-OVA and B16-OVA) with abemaciclib. Abemaciclib increased expression of MHC class I-bound SIINFEKL, an eight-amino-acid peptide derived from OVA (Extended Data Fig. 2e ), confirming enhanced antigen processing and presentation. Co-culture of abemaciclib-pretreated tumour cells with MHC-class-I-restricted OVA-specific CD8 + T cells (OT-I cells) significantly increased OT-I cell proliferation, interferon-γ (IFN-γ ) production, and tumour-necrosis factor-α (TNF-α ) production ( Fig. 1g and Extended Data Fig. 2f, g ). CD8
+ T-cell proliferation was both antigen-specific (P14 CD8 + T cells, which recognize an irrelevant antigen, did not increase their proliferation) and MHC-class-I-specific (MHC class I blocking antibody partly suppressed OT-I T-cell proliferation) ( Fig. 1g and Extended Data Fig. 2f ).
In agreement with other reports 2, 6 , abemaciclib did not directly induce breast cancer cell apoptosis; rather, it caused cell cycle arrest and induced cellular phenotypes consistent with senescence (Extended Data Fig. 3a, b) . Cellular senescence has been associated with apoptosis resistance 8 ; indeed, abemaciclib reduced tumour cell poly(ADP-ribose) polymerase cleavage and suppressed the apoptotic response to staurosporine (Extended Data Fig. 3c, d ). Collectively, these results establish that CDK4/6 inhibitors induce breast cancer cell cytostasis without directly causing their apoptosis, and enhance their capacity to present antigen and stimulate cytotoxic T cells.
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We next sought mechanistic insight for the increase in antigen presentation after CDK4/6 inhibition. Genome-wide transcriptomic analysis of three human breast cancer cell lines and PDX 14-07 tumours revealed that abemaciclib upregulated expression of genes within GO terms related to IFN signalling and cellular defence response to virus (Fig. 2a, b and Extended Data Fig. 4a ). Several IFN-sensitive transcription factors (for example, STAT1, STAT2, IRF2, IRF6, IRF9, and NLRC5) were upregulated in all three cell lines, PDX 14-07 tumours, and MMTV-PyMT-S2WTP3 cells (Fig. 2c, d and Extended Data Fig. 4b, c) . Similar trends were observed when abemaciclib was given in conjunction with anti-oestrogen therapy-the current standard in luminal breast cancer treatment (Extended Data Fig. 4d ). Expression of other IFN-stimulated genes (ISGs)-OAS1, OAS2, IFIT1, IFIT2, BST2, SP100, RSAD2-was also enhanced in cell lines and PDX tumours, suggesting global upregulation of an IFN-driven transcriptional program (Extended Data Fig. 4e, f) . Consistent with active IFN signalling, both phosphorylated and total STAT1 protein were increased after abemaciclib treatment (Extended Data Fig. 4g ). Furthermore, forced overexpression of the endogenous CDK4/6 inhibitor CDKN2A (encoding p16
INK4a
) increased expression of STAT1, B2M, and MHC class I genes (Extended Data Fig. 4h ), suggesting that these are 'on-target' effects.
Importantly, we made similar observations in MMTV-rtTA/tetO-HER2 tumour tissues after abemaciclib treatment. Enriched GSEA expression signatures included 'allograft rejection' , 'interferon alpha response' , and 'interferon gamma response' (Fig. 2e) . Specifically, abemaciclib also significantly increased tumour expression of IFNresponsive transcription factors in these tumours (Fig. 2f) , as well as that of IFN-inducible T-cell chemoattractants and other ISGs involved in lymphocyte adhesion and co-stimulation (Extended Data Fig. 4i, j) . STAT1 protein levels were also higher within tumour cells of the abemaciclib-treated cohort (Fig. 2g) . In keeping with their roles in regulating antigen presentation via MHC class I, in vivo expression of transcription factors Stat1 and Nlrc5 was tightly correlated with that of H2d1, H2k1, Tap1, Tap2, and Tapbp in MMTV-rtTA/tetO-HER2 tumours (Extended Data Fig. 4k ). Thus, CDK4/6 inhibition directly induces ISG expression in tumour cells, probably explaining their enhanced capacity for antigen presentation.
We next interrogated genome-wide expression data from the NeoPalAna trial, in which patients with primary oestrogen-receptorpositive breast cancer underwent tumour biopsies before starting palbociclib and serially after 2 and 12 weeks of treatment (Extended Data Fig. 5a ) 9 . As expected, palbociclib treatment significantly downregulated genes within the 'E2F target' and other cell-cycle-related signatures (Extended Data Fig. 5b ). When we compared upregulated genes from biopsies taken before initiation of palbociclib with those after 12 weeks of treatment, three of the top five ranked 'Hallmarks' GSEA signatures were 'allograft rejection' , 'inflammatory response' , and 'interferon gamma response' (Fig. 2h) , and these gene sets were already significantly upregulated after 2 weeks of palbociclib treatment (Extended Data Fig. 5c ). These signatures are similar to those we observed to be upregulated in the tumours from abemaciclib-treated MMTV-rtTA/tetO-HER2 mice (Fig. 2e) , and demonstrate the clinical relevance of our findings.
We speculated that heightened ISG expression after CDK4/6 inhibition might be caused by enhanced production of tumour cell IFN. The Janus kinases (JAKs) mediate intracellular signalling after liganddependent activation of IFN receptor, and the JAK inhibitor ruxolitinib completely mitigated abemaciclib-induced increases in tumour cell p-STAT1 and total STAT1 (Extended Data Fig. 6a ), suggesting that CDK4/6 inhibition stimulates production of tumour cell IFN. Notably, enzyme-linked immunosorbent assay (ELISA) did not detect IFN-α , -β , or -γ in conditioned medium of abemaciclib-treated tumour cells (not shown), and neutralizing antibodies against IFN-α and IFN-γ , did not mitigate IFN signalling (Extended Data Fig. 6b-d) . However, gene expression and protein secretion of type III IFNs (interleukin (IL)-29, IL-28a, and IL-28b) were significantly increased in abemaciclib-treated tumour cells (Fig. 3a and Extended Data Fig. 6e, f) . Neutralizing antibodies to type III IFNs reversed abemaciclib-induced increases in tumour cell p-STAT1 and total STAT1 (Fig. 3b) . Collectively, these data suggest that CDK4/6 inhibition increases tumour cell production of type III IFNs to drive ISG expression in an autocrine fashion.
Increased tumour cell IFN signalling via type III IFN production has previously been shown to occur in response to DNA demethylation caused by agents such as 5-azacytidine, which inhibits DNA methyltransferases (DNMTs) 10 . In that context, DNMT inhibition reduces methylation of endogenous retroviral genes (ERVs), triggering 'viral mimicry' and a double-stranded RNA (dsRNA) response, in turn stimulating type III IFN production to activate ISGs 10 . Notably, the mammalian DNA methyltransferase gene DNMT1 is a bona fide E2F target gene, and CDK4/6 enzyme activity can enhance DNMT1 gene n = 3) and PDX tumours (f) (21-28 days; vehicle, n = 4; abemaciclib, n = 2 tumours) after abemaciclib treatment. DMSO, dimethylsulfoxide. g, CD8 + T-cell proliferation in response to abemaciclib-pretreated B16-OVA cells (OT-I + anti-IgG1, n = 6; other conditions, n = 3; one-way ANOVA adjusted for multiple comparisons). Unpaired two-tailed t-tests (d-f). Error bars, s.d., except (a) s.e.m. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001. For source data, see Supplementary Table 2. expression in a RB-E2F-dependent fashion 11 . Strikingly, tumour cell levels of DNMT1 (but not DNMT3A) mRNA and protein fell markedly and rapidly in abemaciclib-treated cell lines ( Fig. 3c and Extended Data Fig. 7a-c) . Similarly, abemaciclib reduced DNMT1 mRNA levels in vivo in both PDX 14-07 and MMTV-rtTA/tetO-HER2 tumours ( Fig. 3d and Extended Data Fig. 7d ). These were on-target effects, as abemaciclib did not reduce DNMT1 levels in tumour cells expressing short hairpin RNA (shRNA) targeting RB1 (Extended Data Fig. 7e ). The abemaciclib-related increases in IFNL2, STAT1, and HLA-B expression were also mitigated in shRNA-RB1 cells (Extended Data Fig. 7e ), supporting the concept that the RB-E2F-DNMT1 axis mediates type III IFN production and its downstream consequences.
Consistent with previous studies 10, 12 , suppression of DNMT1 was associated with reduced DNA methylation at ERV sequences: combined bisulfite restriction analysis showed that abemaciclib decreased tumour cell DNA methylation at the 5′ long terminal repeat (LTR) of ERV3-1 (Extended Data Fig. 7f ). Accordingly, expression of certain ERVs was increased in vitro and in vivo (Fig. 3e, f and Extended Data Fig. 7g ), accompanied by significantly higher levels of dsRNA within tumour cells (Fig. 3g and Extended Data Fig. 7h ). In turn, expression of the dsRNA pattern recognition receptors RIG-1 (DDX58), LGP2 (DHX58), and MDA5 (IFIH1) was significantly increased in cell lines and PDX tumours (Extended Data Fig. 7i, j) . In further support of abemaciclib-mediated DNMT1 suppression as the trigger for this cascade of events, overexpression of DNMT1 in tumour cells attenuated the abemaciclib-induced increase in expression of dsRNA response genes, type III IFN, and ISGs ( Fig. 3h and Extended Data Fig. 7k ). Independent of altered ERV expression, CDK4/6 inhibitors could theoretically increase tumour cell immunogenicity by inducing a 'senescence associated secretory phenotype' (SASP) 13 . Although abemaciclib increased tumour cell β -galactosidase activity (Extended Data Figs 3b and 8a), expression of key SASP factors was not increased (Extended Data Fig. 8b , c and Supplementary Table 1 ). In contrast, doxorubicin increased tumour cell expression of SASP genes (Extended Data Fig. 8d) , consistent with the notion that the SASP is more pertinent to DNA damage response-associated senescence 13 and does not explain tumour immunogenicity after CDK4/6 inhibition. 
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Ir f 7 Ir f 8 Ir f 9 Mann-Whitney test (h); Error bars, s.d. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001. For all GSEA, nominal P < 0.001, false discovery rate q < 0.001. (T Reg cells, Fig. 4b ). Circulating T Reg numbers were also significantly lower (Extended Data Fig. 9b ). These results were upheld in MMTVPyMT mammary and CT-26 colorectal carcinomas (Extended Data Fig. 9c, d) . Moreover, the T Reg :CD8 T-cell ratio decreased significantly in abemaciclib-treated tumours, further suggesting a tipping of the immune balance in favour of anti-tumour immunity (Fig. 4c) .
In tumour-free mice, both abemaciclib and palbociclib significantly reduced T Reg numbers and the T Reg :CD8 ratio in the spleen and lymph nodes, demonstrating tumour-independent effects of these agents ( Fig. 4d and Extended Data Fig. 9e, f) . Plasma levels of anti-nuclear and anti-dsDNA antibodies were unchanged (data not shown; Extended Data Fig. 9g ), indicating no significant accompanying autoimmune phenotype. To understand why T Reg cells were reduced in number, we analysed the impact of CDK4/6 inhibitors on various aspects of T Reg biology. Palbociclib and abemaciclib each significantly reduced total thymic mass, decreased immature CD4
+ double-positive thymocytes, and increased the fractions of CD4 + and CD8 + singlepositive thymocytes (Extended Data Fig. 9h-k) , consistent with previous reports of CDK6 inhibition 14 . However, proportions of thymic T Reg cells were unchanged, arguing against a defect in thymus-derived T Reg production (Extended Data Fig. 9l) . Similarly, CDK4/6 inhibitors did not prevent in vitro differentiation of naive CD4 + T cells into T Reg cells, and did not affect rates of T Reg apoptosis (Extended Data Fig. 9m, n) . We then turned our attention to T Reg proliferation. In vitro, abemaciclib markedly reduced the proliferation of CD4 +
CD25
+ T Reg cells isolated from spleens and lymph nodes of wild-type mice, but had a weaker effect on the proliferation of CD4 +
− and CD8 + T cells (Fig. 4e) . Likewise, the fraction of proliferating T Reg cells, but not CD8 + T cells, within abemaciclib-treated tumour tissue was significantly reduced (Fig. 4f and Extended Data Fig. 9o ). DNMT1 inhibition in T Reg cells has previously been reported to suppress their proliferation, ostensibly via hypomethylation of the Cdkn1a promoter, thus increasing expression of the Cdkn1a protein p21-a potent and promiscuous cell cycle inhibitor 15 . In tumour-free mice treated with abemaciclib for 12 days, Dnmt1 expression was reduced in T Reg cells by ~ 70%; in contrast, Dnmt1 mRNA was unchanged in naive CD4
+ T cells and fell by only 20% in CD8 + T cells (Extended Data Fig. 9p ). Mirroring the magnitude of these changes, expression of Cdkn1a increased 75-fold in T Reg cells, 2.8-fold in CD8 + T cells, and was unchanged in naive CD4 + T cells (Extended Data Fig. 9q) . Therefore, the relatively selective suppression of T Reg proliferation after CDK4/6 inhibition could relate to enhanced cell cycle inhibition due to overexpression of p21, associated with reduced levels of DNMT1.
Tumour cells presenting antigen via MHC class I can be recognized by cytotoxic T lymphocytes (CTLs), and T Reg cells suppress CTL responses, in part by promoting their exhaustion 16 . Therefore, to determine whether CTLs were involved in abemaciclib-mediated therapeutic efficacy, we implanted MMTV-rtTA/tetO-HER2 tumour fragments orthotopically into athymic Foxn1 nu mice maintained on doxycycline, and treated them once tumours were established. In contrast to tumours in immunocompetent mice, abemaciclib-treated tumours in nude mice continued to grow, albeit at a significantly slower rate than vehicle-treated tumours, and in no case did tumours regress (Extended Data Fig. 10a, b) . We therefore treated MMTV-rtTA/ tetO-HER2 tumour-bearing mice with an anti-CD8 antibody before abemaciclib administration. Abemaciclib-induced tumour regression, which was observed in control IgG-treated mice, was significantly mitigated by CD8 neutralization (Fig. 4g and Extended Data Fig. 10c) . , j) , s.e.m. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001. For source data, see Supplementary Table 2. Hence, tumour regression mediated by CDK4/6 inhibition is, at least in part, dependent on the presence of CTLs.
Intratumoural CD8 + T cells in abemaciclib-treated mice displayed markedly reduced expression of PD-1, Tim-3, CTLA-4, and LAG3 ( Fig. 4h and Extended Data Fig. 10d-g ), markers typically indicative of T-cell exhaustion 17 . The number of inhibitory receptors detected on any given CTL was lower in abemaciclib-treated MMTV-rtTA/ tetO-HER2 and MMTV-PyMT tumours (Fig. 4i and Extended Data  Fig. 10h) . Specifically, the fractions of both PD-1 high and PD-1 + / TIM-3 + CTLs were significantly reduced ( Fig. 4h and Extended Data  Fig. 10d) . Levels of Ifng mRNA (the main effector cytokine of CTLs) were more than fourfold higher in abemaciclib-treated bulk tumour tissues (Extended Data Fig. 10i) . Collectively, these results indicate that CDK4/6 inhibition results in activation of CTLs, which are necessary for abemaciclib-induced tumour regression.
Increased tumour cell antigen presentation coupled with antitumour T-cell responses suggested that immune checkpoint blockade might further enhance the efficacy of abemaciclib. We treated MMTVrtTA/tetO-HER2 tumour-bearing mice with either vehicle or abemaciclib, and a control IgG or an anti-PDL1 antibody (Extended Data  Fig. 10j ). In agreement with our initial experiments, abemaciclibtreated tumours initially decreased in volume before stabilizing and ultimately resuming growth by day 21 (Fig. 4j) . In contrast, tumours in mice treated with abemaciclib and anti-PDL1 combination therapy regressed to the greatest degree (~ 70% reduction in tumour volume by day 13), and did not resume growth by day 35 ( Fig. 4j and Extended Data Fig. 10k ). Similar results were obtained for the CT-26 colorectal carcinoma model, wherein combination therapy induced complete tumour regression in all cases, and rendered mice disease-resistant when re-challenged with a subsequent injection of CT-26 tumour cells 5 weeks after stopping therapy (Extended Data Fig. 10l, m) .
Collectively, our data in cell lines, animal models, and patients with breast cancer demonstrate that CDK4/6 inhibitors enhance antitumour immunity by overcoming two central mechanisms of tumour immune evasion (Extended Data Fig. 10n ). First, they increase the functional capacity of tumour cells to present antigen. Second, they reduce the immunosuppressive T Reg population by suppressing their proliferation. Intriguingly, these phenomena might not only cooperate to enhance tumour immunogenicity, but could also have the same mechanistic underpinning: suppression of the RB-E2F axis, leading to reduced DNMT1 expression and thus hypomethylation of genes that regulate immune function 10, 12, 15 . The selective suppression of T Reg proliferation (and not that of CD8 + or conventional CD4 + T cells) might relate to the fact that T Reg cells express higher levels of Rb1, a key mediator of CDK4/6 pathway modulation 18 (for example, Rb1 expression is 3.1-fold higher in T Reg cells than in CD8 + T cells 19 ). With respect to breast cancer specifically, we note that most human breast cancers are oestrogen-receptor positive, and these tumours are considered inherently less immunogenic. Interestingly, they generally retain retinoblastoma tumour suppressor function and, furthermore, a high number of T Reg cells in these tumours predicts a poor clinical outcome 20 . Our findings therefore suggest that CDK4/6 inhibitors might enhance the susceptibility of such tumours to immune checkpoint blockade.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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MethODS
Animal experiments. MMTV-rtTA/tetO-HER2 mice 6 were maintained in house. Female FVB MMTV-PyMT, Balb/c (6-7 weeks old) and Foxn1 nu (8 weeks old) mice were purchased from The Jackson Laboratory. Female FVB mice (7 weeks old) were purchased from Taconic Biosciences. P14-TCR transgenic mice (a gift from K. Wucherpfennig) and OT-I mice (C57BL/6 Tg(TcraTcrb)1100Mjb/J; The Jackson Laboratory) were used as a source of CD8 + T cells for in vitro co-culture assays. FVB CD45.2 + mice (a gift from D. Tenen) were used as a source of T cells for in vitro studies.
Tumours were induced and maintained in MMTV-rtTA/tetO-HER2 mice using doxycycline as previously described 6 . For experiments in transgenic MMTV-rtTA/ tetO-HER2 and MMTV-PyMT mice, tumours measured 4-10 mm at treatment initiation. Before treatment, mice were assigned into groups of equal average tumour volume. For CT-26 experiments, 1 × 10 5 tumour cells were injected subcutaneously in 1:1 PBS:Matrigel into Balb/c mice, and treatment was initiated 1 week later. For re-challenge experiments, 5 × 10 5 tumour cells were injected subcutaneously in 1:1 PBS:Matrigel 33 days after treatment was stopped. PDX 14-07 was established from a biopsy of a liver metastasis from a patient with ER +
/Her2
+ breast cancer as previously described 6 . For studies in Foxn1 nu mice, MMTV-rtTA/tetO-HER2 tumour fragments were orthotopically implanted bilaterally into nude mice, as previously described 6 . Before treatment initiation, mice were randomized into groups of equal average tumour volume (5-10 mm diameter).
For in vivo experiments, samples sizes were determined on the basis of knowledge of inter-tumour growth rate variability, gained from previous model-specific experience. Tumour-bearing mice were randomly assigned to treatment groups, ensuring that baseline tumour volumes were balanced between treatment arms. Tumours were measured by calliper two or three times per week, and the volume was calculated as previously described 6 . For tumour growth kinetic analysis, we performed two-way ANOVA or one-way ANOVA tests with correction for multiple comparisons using Sidak's multiple comparisons test. No animals were excluded from analyses. Ex vivo analyses of mouse tissues were performed in a blinded fashion such that the investigators were unaware of treatment groups. Source data for tumour volume measurements can be found in Supplementary Table 2 .
Abemaciclib (75-90 mg per kg (body weight), as noted for individual experiments, Haoyuan Chemexpress, prepared as previously described 6 ) and palbociclib (90 mg per kg, Haoyuan Chemexpress, diluted in 50 nM sodium d-lactate) were administered daily by oral gavage. For CD8 depletion experiments, mice were injected intraperitoneally with either α -CD8 antibody (400 μ g; clone YTS 169.4, BioXcell) or isotype control (400 μ g; clone LTF-2, BioXcell) 48 and 24 h before beginning abemaciclib therapy (90 mg per kg) and every 4 days thereafter. For combination therapy, treatment with abemaciclib was initiated at a dose of 90 mg per kg daily for 3 days; thereafter, the dose was dropped to 75 mg per kg daily and intraperitoneal injection of either α -PDL1 antibody (200 μ g every 72 h; BioXcell, clone 10F.9G2) or isotype control antibody (200 μ g every 72 h, clone LTF-2, BioXcell) was added to the regimen.
Mice were euthanized using CO 2 inhalation. All mouse experiments were performed in compliance with federal laws and institutional guidelines as approved by the Institutional Animal Care and Use Committees of Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital. The maximum tumour diameter permitted under the relevant animal protocols is 25 mm, and this limit was not exceeded in any experiment. Immunohistochemistry and immunofluorescence. Immunostaining for Ki-67 (Vector), HER2 (AB16901; Abcam), and STAT1 (AB47425; Abcam) was performed as previously described 6 . Secondary antibodies (AF488 AffiniPure donkey anti-mouse IgG, Cy3 AffiniPure donkey anti-rabbit IgG) were from Jackson ImmunoResearch Laboratories. Images were acquired with a Yokogawa spinning disk confocal on an inverted Nikon Ti fluorescence microscope using MetaMorph image acquisition software, and three to five fields were analysed per tumour. Image analysis was performed using a semi-automated in-house platform (NIH ImageJ).
Immunofluorescence for FoxP3 (clone FJK-16 s; eBioscience), CD8 (clone 4SM15; eBioscience), and Ki-67 (clone SP6; Thermo Scientific) was performed as previously described 21 . Secondary antibodies (AF488 donkey anti-rabbit IgG, AF647 goat anti-rat IgG) were from Life Technologies. Tissues were counterstained with DAPI (Invitrogen). Images were acquired on a Nikon Eclipse Ni microscope using NIS Elements software, and five to ten fields were analysed per tumour. Human cell lines. BT474, SKBR3, MDA-MB-361, MDA-MB-453, and MCF7 human breast cancer cell lines were maintained as previously described 6 with slight modifications: antibiotics and anti-fungals were not used in cell culture media. MCF7 cells were cultured in RPMI medium (Gibco) supplemented with 10% FBS (Gibco). All cell lines were obtained from American Type Culture
Collection (ATCC), tested negative for mycoplasma, and their identity was verified by short tandem repeat analysis (Promega GenePrint 10 System). Mouse cell lines. MMTV-PyMT-S2WTP3 cells 22 (a gift from A. Möller) were cultured in DMEM (Gibco) supplemented with 10% FBS (Gibco). B16-OVA cells 23 were cultured in DMEM supplemented with 10% FBS and 250 μ g ml
G418 (Invitrogen). CT-26 cells (a gift from S. Elledge) were cultured in RPMI (Gibco) supplemented with 10% FBS. All cell lines tested negative for mycoplasma, and their mouse strain of origin was confirmed by short tandem repeat analysis (Bioassay Methods Group, National Institute of Standards and Technology).
In vitro drug studies. Abemaciclib and lapatinib (Haoyuan Chemexpress) were diluted as previously described 6 . For in vitro use, palbociclib was diluted in DMSO. Cleaved poly (ADP-ribose) polymerase-1 (PARP) was measured after 48 h of treatment with DMSO, lapatinib, or abemaciclib. Lapatinib was used at 30 nM for BT474 and SKBR3; 500 nM for MDA-MB-453 and MDA-MB-361. Abemaciclib was used at 300 nM for BT474 and SKBR3; 25 nM for MDA-MB-453; 500 nM for MDA-MB-361. For staurosporine experiments, MDA-MB-453 cells were pretreated with DMSO or abemaciclib (500 nM) for 0, 1, or 7 days before exposure to staurosporine (500 nM, Enzo Life Sciences) for 4 h. For hormonal therapy studies, cells were treated with combinations of DMSO, abemaciclib (100 nM), and fulvestrant (100 nM, Sigma Aldrich). To determine JAK dependency, cells were treated with combinations of DMSO, abemaciclib (500 nM), and ruxolitinib (500 nM, Selleckchem) for 7 days. Western blots. Western blotting was performed as previously described 6 using antibodies to cleaved PARP (CST 9541), cleaved caspase-3 (CST 9661), phospho-STAT1 Y701 (CST 9167), STAT1 (CST 9172), and Flag (CST 2368) (Cell Signaling Technologies), vinculin (V9131, Sigma) and DNMT1 (92314, Abcam). For western blots assessing phosphorylated and total STAT1 in tumour cells, lysates from equivalent numbers of cells were loaded in each lane. Uncropped western blots can be found in Supplementary Fig. 1 . β-Galactosidase activity. Senescence-associated β -galactosidase expression was determined as previously described 6 . Transcriptome methodology. AmpliSeq libraries were constructed and sequenced on the Ion Torrent Proton platform (Thermo Fisher) according to the manufacturer's instructions as previously described 24, 25 . For human gene analysis in cell lines, the Ion AmpliSeq Transcriptome Human Gene Expression Kit is designed for targeted amplification of over 20,000 human RefSeq genes simultaneously in a single primer pool. A short amplicon (~ 110 base pairs (bp)) is amplified for each targeted gene. Since an AmpliSeq transcriptome mouse kit is not commercially available, an Ion AmpliSeq Custom Panel was designed by the manufacturer (Thermo Fisher) using Ion AmpliSeq Designer for targeted amplification of 3,826 mouse genes that were most relevant for our studies (one short amplicon for each gene) in one primer pool for mouse studies. For each sample, 10 ng of total RNA was used for cDNA library preparation. Multiple libraries were multiplexed and clonally amplified using the Ion OneTouch 2 System (Thermo Fisher), and then sequenced on an Ion Torrent Proton machine (Thermo Fisher). Data were first analysed by Torrent Suite and ampliSeqRNA analysis plugin (Thermo Fisher) to generate count data. Mouse transcriptome analysis. Raw read counts per gene were mapped to corresponding human homologues, using homology information from the Mouse Genome Informatics database (The Jackson Laboratory). For GO analysis, differential gene expression was determined using DESeq2 (ref. 26) and genes were ranked according to log 2 (fold change) (maximum a posteriori). For GSEA analysis, we used the GSEAPreranked tool, with the above-ranked gene list, using MSigDB v5.1 Hallmarks gene sets collection and the 'classic' method for calculating enrichment scores 27, 28 . Human transcriptome analysis. Analyses were performed on normalized read counts per gene. For GO analysis, only genes with an absolute read count of > 20 on at least one sample were included. For these genes, the fold change in normalized read count was determined for each replicate experiment, and the mean fold change was calculated for each gene. Genes with a mean fold change of > 2 (DMSO versus abemaciclib) were then included for analysis using Gene Ontology enrichment analysis. TCGA analysis. Gene expression data were obtained using the cBioPortal for Cancer Genomics (http://www.cbioportal.org). Data were obtained from the breast cancer data set 'TCGA, Provisional (1105 samples)' for comparisons between cyclin D1 shallow deletion, amplified, gain, and diploid tumours 7, 29 . Reverse transcription quantitative PCR. Reverse transcribed quantitative PCR (RT-qPCR) was performed as previously described 6 . Primer sequences used for qPCR were as follows. Ifng (mouse) forward: 5′ -ATG-AAC-GCT-ACA-CAC-TGC-ATC-3′ ; reverse: 5′ -CCA-TCC-TTT-TGC-CAG-TTC-CTC-3′ . Tap1 (mouse) forward: 5′ -GGA-CTT-GCC-TTG-TTC-CGA-GAG-3′ ; reverse: 5′ -GCT-GCC-ACA-TAA-CTG-ATA-GCG-A-3′ . Tap2 (mouse) forward: 5′ -CTG-GCG-GAC-fold-change difference in the gene of interest relative to GAPDH or HSP90AB1 (human), or Actb or Hsp90ab1 (mouse). qPCR was performed on an Applied Biosystems 7300 machine. Flow cytometry. Tumour cell lines: one million cells per condition were stained with the appropriate antibodies diluted in PBS (Hyclone) plus 2% FBS (Life Technologies) for 30 min on ice. Matched fluorescence minus one (FMO) staining for each condition was performed as a control.
Blood: this was obtained by retro-orbital sampling at intermediate time points and by cardiac puncture at experimental end points. Blood cells and plasma were separated by centrifugation at 1,500g for 8 min at 4 °C.
Spleen, thymus, and lymph nodes: single-cell suspensions were obtained by mechanical digestion.
Tumour: tumours were first mechanically disrupted by chopping, then chemically digested in dissociation buffer (2 mg ml −1 collagenase type IV (Worthington Biochemical), 0.02 mg ml −1 DNase (Sigma Aldrich) in DMEM (Life Technologies) containing 5% FBS (Life Technologies), PenStrep (Hyclone)) with agitation at 37 °C for 45 min.
After lysis of red blood cells if necessary (blood, spleen, thymus, tumour; PharmLyse, BD Biosciences), single-cell suspensions were blocked with anti-CD16/32 (Biolegend) for 20 min on ice and then incubated with appropriate antibodies for 30 min on ice.
Mouse antibodies: antibodies were purchased from Biolegend unless otherwise indicated: CD45 (clone 30-F11), CD3 (clone 145-2C11), CD8 (clone 53-6.7), CD4 (clone RM4-5), PD-1 (clone 29F.1A12), Tim-3 (clone RMT3-23), CTLA-4 (clone UC10-4B9), LAG-3 (clone C9B7W), B220 (clone RA3-6B2), NK1.1 (clone PK136), CD11b (clone M1/70), Ly6G (clone 1A8), Ly6C (clone AL-21; BD Pharmigen), and FoxP3 (clone FJK-16 s; eBioscience). Human antibodies: β 2-microglobulin (clone 2M2) and HLA-A, -B, -C (clone W6/32). Anti-mouse/rat FoxP3 staining set (eBioscience) was used for intracellular staining according to the manufacturer's instructions. dsRNA was detected by the K1 antibody (English and Scientific Consulting (Hungary)) using 75% ethanol for fixation. To distinguish live/dead cells, 7AAD was used, except in cases requiring intracellular staining for which eFluor 450 (eBioscience) or Zombie Yellow (Biolegend) fixable viability dyes were used. To determine the absolute number of cells in a sample, CountBright absolute counting beads (Molecular Probes, ThermoFisher) were added. Flow cytometry was performed on an LSRII (BD Biosciences) or FACSCANTOII (BD Biosciences), and data were analysed using FlowJo (TreeStar). Flow cytometry gating strategies can be found in the Supplementary Methods (regulatory T-cell gating strategy, Supplementary Methods 1; thymic cell populations, Supplementary Methods 2; and immune checkpoint molecules on intratumoural T cells, Supplementary Methods 3). Tumour cell/OT-I co-culture assay. MMTV-PyMT-S2WTP3-OVA and B16-OVA cells were pretreated with abemaciclib (500 nM or 1,000 nM, respectively) or DMSO for 7 days. Tumour cells were pre-incubated with 40 μ g ml + T cells were isolated from spleens and lymph nodes of OT-I or P14 mice using a CD8a , and infected cells were isolated by fluorescence-activated cell sorting.
MDA-MB-453 and BT474 cells were transient transfected with pBabepuro3-p16Flag (Addgene catalogue number 24934) using Lipofectamine 3000 (Thermo Fisher) according to the manufacturer's instructions. Seventy-two hours after transfection, cells were selected in puromycin for 48 h. Overexpression of p16 was confirmed by anti-Flag western blots.
For overexpression of DNMT1, MDA-MB-453 cells were transfected with the pcDNA3/Myc-DNMT1 vector (Addgene catalogue number 36939) using Lipofectamine 3000 according to the manufacturer's instructions. Cells were treated with abemaciclib 72 h after transfection. ELISAs. Cells were treated with DMSO or abemaciclib (500 nM) for 7 days. For the last 24 h, culture media were replaced with serum-free media. After concentration of conditioned medium using Amicon Ultra centrifugal filters (Millipore), cytokines were analysed according to the manufacturer's recommendations: human IFN gamma ELISA Ready-SET-Go! (Affymetrix eBioscience), human TNF alpha ELISA Ready-SET-Go! (Affymetrix eBioscience), Verikine human IFN alpha ELISA kit (PBL assay science), VeriKine-HS human IFN beta serum ELISA kit (PBL assay science), human IL-28B quantikine ELISA kit (R&D Systems), human IL-28A DuoSet ELISA (R&D Systems), and human IL-29 DuoSet ELISA (R&D Systems). Cytokine production by OT-I T cells in OVA/OT-I co-culture assays was measured by mouse IFN gamma ELISA Ready-SET-Go! (Affymetrix eBioscience) and a mouse TNF-alpha Quantikine ELISA Kit (R&D Systems) according to the manufacturer's instructions. Anti-ANA and anti-dsDNA ELISAs (Alpha Diagnostic) were performed on plasma according to the manufacturer's instructions. Absorbance was measured on a Synergy Neo plate reader (BioTek) using Gen5 software. IFN neutralization experiments. Cell lines were treated with DMSO or abemaciclib (500 nM) for 7 days. For the duration of drug treatment, neutralizing antibodies were applied including IFN-γ (1 μ g ml −1 , R&D Systems, MAB2851), IFN-α (2.0-2.5 μ g ml −1 , R&D Systems, 21100-1), IL-28a (0.5 μ g ml −1 , R&D Systems, MAB1587), or IL-29 (1 μ g ml −1 , R&D Systems, MAB15981-100). Successful neutralization was validated using recombinant human IFN-γ (Peprotech, 250 pg ml ). Recombinant proteins were administered 24 h before protein collection. Analysis of methylation of the ERV3-1 5′-LTR. Genomic DNA was extracted from cells and subjected to RNase treatment before standard bisulfite conversion (MethylEdge Bisulfite Kit, Promega). Bisulfite DNA was subjected to PCR, and then a second nested PCR, to amplify the 5′ -LTR of ERV3-1 using the method and primers as previously described 30 to amplify a DNA fragment of 644 bp. The PCR product was enzymatically digested using the RsaI restriction enzyme (New England Biolabs). Owing to a CG site in the native DNA within this amplicon, this digestion cuts methylated DNA amplicons into ~ 317 bp and ~ 327 bp fragments, leaving the non-methylated DNA uncut. shRNA experiments. Two shRNA constructs to RB1 (TRC identifiers TRCN0000295892 and TRCN0000295842) and shLuciferase control were expressed in tumour cells as previously described 6 . Suppression efficiency was validated by RT-qPCR. Doxorubicin-induced senescence. MDA-MB-453 and BT474 cells were treated with doxorubicin (Sigma Aldrich, 200 nM) for a period of 24 h. The cells were then cultured in fresh media for 72 h after treatment, and RNA was extracted for qPCR.
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In vitro regulatory T-cell differentiation. CD4 +
CD25
− T cells were isolated from spleens and lymph nodes of naive FVB mice using a CD4 + CD25 + Regulatory T Cell Kit (Miltenyl Biotec) with an autoMACs Pro Separator. Cells were cultured for 72 h in T-cell medium with CD3/CD28 Dynabeads (1:1 ratio of cells:beads, ThermoFisher), 100 U ml −1 rhIL-2 (Peprotech), with or without 25 ng ml + T cells were isolated as described above. Isolated T cells were labelled with 5 μ M CFSE (Biolegend) as described above. 1 × 10 5 cells were cultured in T-cell medium with CD3/CD28 beads (1:1 ratio of cells to beads), 100 U ml −1 rhIL-2 and DMSO or abemaciclib (250 or 500 nM) for 72 h at 37 °C. CFSE-dilution was analysed at end point by flow cytometry.
Gene expression in isolated T-cell populations. CD8
+ , CD4 + CD25 − , and CD4 + CD25 + T cells were isolated as described above from lymph nodes and spleens of naive FVB mice treated with vehicle or 90 mg per kg abemaciclib for 12 days. Purity of isolated populations was confirmed by flow cytometry. mRNA was obtained using a NucleoSpin RNA XS Kit (Macherey-Nagel) according to the manufacturer's instructions. RT-qPCR was performed as described above. Patient data. Gene expression data (GEO GSE93204) were obtained from biopsy samples from the NeoPalAna clinical trial (NCT01723774) 9 . Expression data were used in the log 2 -normalized form. We used GSEA software (Broad Institute, Massachusetts, USA) with the following settings for analysis: number of permutations: 1,000; collapse data set of gene symbols: true; permutation type: gene set; enrichment statistic: weighted; metric for ranking genes: Signal2Noise; gene list sorting mode: real; gene list ordering mode: descending; max size/exclude larger sets: 500; min size/exclude smaller sets: 15. Analysis was performed using the 'Hallmarks v6.0' GSEA signatures.
Statistical analyses. Statistical analyses were performed as described in the figure legend for each experiment. All statistical tests were two-sided, and nonparametric tests were used when variance was dissimilar between groups. All data are presented as mean ± s.d. unless otherwise noted in the legends. Differences were considered statistically significant at P ≤ 0.05. All data shown are representative two or more independent experiments, unless indicated otherwise. Data availability. Transcriptomic data that support the findings of this study have been deposited in the Gene Expression Omnibus under primary accession code GSE99063. Source data for western blots and tumour measurements are provided in Supplementary Fig. 1 b SIINFEKL flow cytometry after 7 days of abemaciclib or DMSO (B16-OVA, n = 9; MMTVPyMT-S2WTP3-OVA, n = 3). f, CD8
+ T-cell proliferation in response to abemaciclib-pretreated tumour cells (n = 3). g, IFN-γ and TNF-α production in tumour cell/OT-I assay by ELISA (n = 3). One-way ANOVA adjusted for multiple comparisons (c, d, f), unpaired two-tailed t-tests (a, b, e, g ). Error bars, s.d. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. For in vivo experiments, samples sizes were determined based on previous experience with the models utilized, including experience in variability of tumor growth.
Data exclusions
Describe any data exclusions. No data were excluded from analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental findings were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Prior to treatment initiation, mice were randomized into groups of equal average tumor volume.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
In vivo experiments were performed in a blinded fashion when possible. Downstream analyses of mouse tissue (immunohistochemistry, image analysis, flow cytometry) all experiments were performed in a blinded fashion such that the people conducting and/or analyzing the assay were not aware of treatment groups until data gathering was complete.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
expression, CD3+ CD4+ and CD3+ CD8+ populations were then examined for PD-1, CTLA-4, Tim-3, and LAG-3 expression.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
